Obexelimab

Phase 3Monoclonal antibody

ZZenas BioPharma (USA), LLC

Obexelimab is one of 93 small molecule programs targeting IgG4 Related Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Igg4 Related DiseaseActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

Multiple SclerosisActive, not recruiting

Warm Autoimmune Hemolytic AnemiaActive, not recruiting

Igg4 Related DiseasePhase 3

Active, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Warm Autoimmune Hemolytic AnemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

1 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 3

Vumerity

Biogen

Phase 3

4 4

Frexalimab

Sanofi

Phase 3

2 5

Clemastine Fumarate

Novartis

Phase 3

2 6

Antihistamine

Arrowhead Pharmaceuticals

Phase 3

2 7

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

1 8

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

3 9

Obexelimab

ZZenas BioPharma (USA), LLC

Phase 3

1 10

Tolebrutinib

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Systemic Lupus Erythematosus

NCT06559163

Q1 2029

Phase 3Active, not recruiting

Igg4 Related Disease

NCT05662241

Clinical

Trials by Indication[1]

Warm Autoimmune Hemolytic Anemia1 trial

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

Active, not recruiting·ZZenas BioPharma (USA), LLC·Phase 3·NCT05786573·134 enrolled

Multiple Sclerosis1 trial

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Active, not recruiting·ZZenas BioPharma (USA), LLC·Phase 2·NCT06564311·93 enrolled

IgG4 Related Disease1 trial

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

Active, not recruiting·ZZenas BioPharma (USA), LLC·Phase 3·NCT05662241·194 enrolled

Systemic Lupus Erythematosus1 trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus

Active, not recruiting·ZZenas BioPharma (USA), LLC·Phase 2·NCT06559163·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Obexelimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Obexelimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Obexelimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zenas BioPharma (USA), LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: ZZenas BioPharma (USA), LLC

Obexelimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2029

Trials by Indication[1]

Warm Autoimmune Hemolytic Anemia1 trial

Multiple Sclerosis1 trial

IgG4 Related Disease1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News